Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Radiopharm Theranostics Limited ( (AU:RAD) ) just unveiled an update.
Radiopharm Theranostics has appointed Bruce Goodwin as a Non-Executive Director, bringing over four decades of experience in the life sciences sector, including a significant tenure at Janssen Pharmaceutical Companies of Johnson & Johnson. Goodwin’s strategic acumen and global perspective are expected to enhance Radiopharm’s efforts to advance its pipeline and strengthen its global profile, while the company also announces the retirement of two board members, Phillip Hains and Dr. Leila Alland, with Hains continuing in executive roles.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics is a clinical stage radiotherapeutics company focused on developing innovative radiopharmaceutical products for both diagnostic and therapeutic applications, particularly in areas of high unmet medical need. The company is listed on ASX and NASDAQ and has a pipeline of technologies including peptides, small molecules, and monoclonal antibodies for use in cancer treatment, with ongoing clinical trials targeting various solid tumor cancers.
Average Trading Volume: 6,592,237
Technical Sentiment Signal: Sell
Current Market Cap: A$61.17M
For a thorough assessment of RAD stock, go to TipRanks’ Stock Analysis page.